Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension
نویسندگان
چکیده
منابع مشابه
Effect of regular phosphodiesterase type 5 inhibition in hypertension.
There are no published controlled clinical trials of regular phosphodiesterase type 5 inhibitor therapy as a long-term treatment of hypertension. In a randomized, double-blind, 2-way crossover study, 25 otherwise untreated hypertensive subjects were administered 50 mg of sildenafil or matched placebo 3 times daily for 16 days, and the effects on ambulatory blood pressure (BP), clinic BP, arteri...
متن کاملPhosphodiesterase 5 Inhibition to Treat Essential Hypertension
Treatment of hypertension is a challenging task in cardiovascular medicine. The obviously simple concept that blood pressure (BP) must be “normalized” faces the intrinsic difficulty to decrease BP values, because the effectiveness of available drug classes in terms of BP reduction is in many cases not adequate to reach the therapeutic targets.1 One possible means of overcoming this limitation i...
متن کاملPULMONARY HYPERTENSION Phosphodiesterase type 5 and high altitude pulmonary hypertension
Background: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). Methods: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملPotential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease.
C hronic kidney disease (CKD) is common, affecting 13% of adults in the United States, with 8% having an estimated glomerular filtration rate (eGFR) of <60 mL/min per 1.73 m 2 in the survey from National Health and Nutrition Examination Survey (1999–2004). 1 Prevalence is likely to increase further with an aging population and high levels of obesity, hyperten-sion, and diabetes mellitus and has...
متن کاملPhosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role. This endothelial dysfunction is characterized by an overproduction of vasoconstr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hypertension
سال: 2006
ISSN: 0194-911X,1524-4563
DOI: 10.1161/01.hyp.0000239816.13007.c9